Philippines
+918265041513
+918265041513

Bortenat 3.5mg (Generic Velcade) Dubai — Bortezomib for Myeloma & Lymphoma UAE

Bortezomib — the active ingredient in Velcade and the Indian generic Bortenat 3.5mg — is a cornerstone proteasome inhibitor used in multiple myeloma and mantle cell lymphoma treatment. For Dubai oncology teams, understanding correct dosage and administration is essential for optimal patient outcomes and minimal toxicity.

Bortenat 3.5mg is supplied as a lyophilised powder for reconstitution, given either subcutaneously (SC) or intravenously (IV). The subcutaneous route is now preferred in most Dubai oncology centres, producing equivalent efficacy with significantly lower peripheral neuropathy rates compared to IV administration. The standard myeloma dose is 1.3mg/m² on days 1, 4, 8, and 11 of a 21-day cycle, typically combined with dexamethasone and Lenalidomide or Cyclophosphamide.

Dubai's American Hospital and Mediclinic oncology departments administer Bortezomib as part of standard myeloma combination regimens. Hospital pharmacies in Dubai can source Bortenat at competitive prices through licensed Indian suppliers, with full WHO-GMP documentation for institutional procurement.

Unnati Pharmax supplies Bortenat 3.5mg injection vials to hospital pharmacies and oncology centres in Dubai and the UAE. Contact medshopy.com or WhatsApp +91 82650 41513 for institutional pricing.
 2026-06-22T14:15:07

Keywords